Platform applications


 

SETTING A NEW STANDARD OF NEONATAL RESPIRATORY CARE
PREVENTATIVE CARE FROM THE FIRST BREATH

SCROLL DOWN

Platform applications


 

SETTING A NEW STANDARD OF NEONATAL RESPIRATORY CARE
PREVENTATIVE CARE FROM THE FIRST BREATH

FIRST APPLICATION:
NEONATAL POINT OF CARE LUNG MATURITY TEST (LMT)

Photo by annedehaas/iStock / Getty Images

Respiratory Distress Syndrome (RDS) is an unmet clinical need

RDS, a breathing disorder caused by a lack of surfactant, it is the primary cause of mortality and severe morbidity in preterm babies. Today RDS is diagnosed a few hours after birth by accessing symptoms. Surfactant treatment is then administered, which slows, and eventually halts, disease progression. 


RDS can be prevented with early diagnosis and treatment

Surfactant therapy is highly effective, and if administered minutes after birth it has the potential to prevent RDS. So why not give it to all babies? A COCHRANE REVIEW found that prophylactic treatment can harm healthy babies, therefore an early diagnostic for identifying which babies are at risk of RDS is needed. 


SIME is delivering the world's first rapid RDS diagnostic

Requiring only a small sample of gastric aspirate (fluid routinely extracted from the stomach at birth) SIME can accurately predict RDS within minutes at the point of care. Empowering Doctors to identify which babies are at risk of RDS and require preventative treatment. 


Recent European Guidelines recognise the need for a RDS bedside test

Methods to measure the presence or absence of endogenous surfactant, such as lamellar body count in gastric aspirate, may help in deciding whom to treat. However, methods that require laboratory expertise around the clock are unlikely to be widely adopted and a simple bedside test that can be used within the NICU is needed.
— David G. Sweet et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update, Neonataology 2017;111:107-125.

SIME's LMT test has been scientifically proven, in a clinical pilot study, to predict RDS with HIGH sensitivity 

This lung maturity test has been developed to identify pre-term infants who will benefit from early surfactant treatment. By only rapidly intervening in those infants that need treatment, we can significantly improve RDS clinical outcomes, and potentially lessen the need for mechanical ventilation and oxygen.
— Henrik Verder, Christian Heiring, Howard Clark et al. ACTA Paediatrica 2016

The development of the Lung Maturity Test (LMT) application is supported by EU Horizon 2020 Phase 2 SME Instrument (project no. 666668). 

Platform applications2


MULTIPLE MARKER
POINT-OF-CARE
DIABETES Dx

Platform applications2


MULTIPLE MARKER
POINT-OF-CARE
DIABETES Dx

More information coming soon.